CCO Annual Update
Hepatitis Annual Update 2005
Understanding Mechanisms of Drug Action and Viral Resistance in HBV |
Module 1 of 11 |
|
CME Program Director: Patrick J. Lynch, MD
|
|
Topics covered include:
- Introduction
- HBV Replication: Overview
- Molecular Targets of HBV Treatment
- Molecular Basis for Drug Resistance
- Monitoring Drug Resistance
Learning Objectives
Upon completion of this activity, participants should be able to:
Define molecular targets for antiviral therapy and mechanisms of viral resistance. Review issues of integration, latency, and drug resistance, and describe the assays used for measuring HBV, including DNA and genotype assays. Describe the mechanisms of HBV replication.
|
HBV: Why Do You Treat, Whom Do You Treat, What Are the Endpoints? |
Module 2 of 11 |
|
CME Program Director: Patrick J. Lynch, MD
- Emmet B. Keeffe, MD, MACP
|
|
|
Topics covered include:
- Introduction
- Natural Progression of Chronic HBV Infection
- Why Do You Treat? Cirrhosis and Hepatocellular Carcinoma
- Whom Do You Treat?
- How Do You Treat?
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the different prophylactic and treatment approaches for various individual HBV-infected populations, including those who are HBeAg-positive vs HBeAg-negative, virally coinfected, pregnant, and immunocompromised. Describe the natural history of chronic hepatitis B virus infection and factors involved in proper diagnosis. Review the current and emerging treatment choices in chronic hepatitis B, including advantages and disadvantages of each treatment option.
|
New Data on Hepatitis B Virus Treatment |
Module 3 of 11 |
|
CME Program Director: Patrick J. Lynch, MD
 
- Hui Chee-Kin, MD
- George K. K. Lau, MD
|
|
|
Topics covered include:
- Introduction
- Interferon
- Lamivudine
- Adefovir Dipivoxil
- Peginterferon Alfa
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss preclinical anti-HBV agents. Describe drugs with anti-hepatitis B virus (HBV) activity already approved by the FDA for treatment of HBV or other indications. Review anti-HBV drugs that are currently in clinical trials.
|
Point/Counterpoint: Interferon or Nucleoside/Nucleotide Analogues as First-Line Therapy for Hepatitis B? |
Module 4 of 11 |
|
CME Program Director: Patrick J. Lynch, MD
 
- E. Jenny Heathcote, MD, MRCP, FRCP(C)
- Marion G. Peters, MD
|
|
|
Topics covered include:
- Introduction to Interferon as First-Line Therapy for Chronic Hepatitis B
- Outcome Measures of Response to Antiviral Therapy for Hepatitis B
- Standard Interferon Therapy in HBeAg-Positive Disease: Short-Term Goals
- Standard Interferon Therapy in HBeAg-Positive Disease: Long-Term Goals
- Standard Interferon Therapy in HBeAg-Negative Disease
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe optimal management of chronic HBV using interferons or nucleosides as first-line. Compare the advantages and disadvantages of interferon and nucleoside therapy for treating HBV patients. Review recent studies of interferon and peginterferon as well as nucleosides and nucleotides supporting their use in HBeAg-positive and -negative patients.
|
Molecular Basis of HCV Therapy |
Module 5 of 11 |
|
Program Director: Patrick J. Lynch, MD
- Charles M. Rice, III, PhD
|
|
|
Topics covered include:
- Introduction
- HCV Replication in vivo
- HCV Replication at the Cellular Level
- Model Systems for Studying HCV Replication
- HCV Targets and Approaches for Antiviral Development: Overview
Learning Objectives
Upon completion of this activity, participants should be able to:
Identify which steps in the HCV life cycle are optimal molecular targets of treatment and which compounds and classes of agents are most promising. Review the molecular basis for resistance and cross-genotype efficacy of viral compounds. Describe the key steps in the replication of HCV.
|
Hepatitis C Treatment: 2005 |
Module 6 of 11 |
|
Program Director: Patrick J. Lynch, MD
|
|
Topics covered include:
- Introduction
- Currently Available Treatments: Peginterferon and Ribavirin
- New Drugs in Development: Viramidine
- Other New Drugs in Development
- Challenges in the Treatment of Hepatitis C: African-Americans
Learning Objectives
Upon completion of this activity, participants should be able to:
Recognize challenges in the treatment of hepatitis C in select populations, including African-Americans, patients with renal failure or on dialysis, patients coinfected with HIV-1, those with acute hepatitis C, and nonresponders. Understand the status of new drugs in development for treatment of hepatitis C, including nucleosides and viramidine. Discuss new developments in the treatment of hepatitis C.
|
Treatment for Hepatitis C Nonresponders and Relapsers |
Module 7 of 11 |
|
Program Director: Patrick J. Lynch, MD
|
|
Topics covered include:
- Introduction
- The Basis for Nonresponse: Overview
- Viral Factors
- Host Factors
- Choice of Therapy
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe factors associated with hepatitis C nonresponse and relapse Review data supporting hepatitis C maintenance therapy, including ongoing studies Discuss the role of novel agents, including replication inhibitors, in the treatment of hepatitis C nonresponders and relapsers
|
Managing Side Effects of HCV Therapy |
Module 8 of 11 |
|
Program Director: Patrick J. Lynch, MD
|
|
Topics covered include:
- Introduction
- Strategies for Reducing Treatment-Related Side Effects: Reducing Treatment Duration
- Treatment-Related Neuropsychiatric Symptoms: Depression
- Male Sexual Dysfunction
- Fatigue
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the cytopenic complications associated with ribavirin therapy, including anemia, neutropenia, and thrombocytopenia. Describe the optimal management of hematologic complications due to interferon/ribavirin therapy. Discuss neuropsychiatric complications, retinopathy, and sarcoidosis associated with interferon/ribavirin therapy, and ways of managing these side effects.
|
Current Assessment of Fibrosis |
Module 9 of 11 |
|
CME Program Director: Patrick J. Lynch, MD
|
|
Topics covered include:
- Introduction
- Why Is Fibrosis Assessment So Important Now?
- Types of Tests
- Genomics
- Microarray, Proteomics, and Glycomics
Learning Objectives
Upon completion of this activity, participants should be able to:
Understand the various commercial tests and those in development to measure hepatic fibrosis Describe the value of liver biopsy in assessing fibrosis Contrast the effectiveness of clinical algorithms compared to liver biopsy in assessing hepatic fibrosis
|
Nonalcoholic Fatty Liver Disease |
Module 10 of 11 |
|
CME Program Director: Patrick J. Lynch, MD
|
|
Topics covered include:
- Relationship of Insulin Resistance with NAFLD
- Metabolic and Biochemical Consequences of Insulin Resistance
- Insulin Resistance and the Development of a Fatty Liver
- From Fatty Liver to Steatohepatitis: Insulin Resistance and the Two-Hit Hypothesis
- Role of Mitochondria
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe optimal management of nonalcoholic fatty liver disease and emerging pharmacologic treatments for nonalcoholic steatohepatitis Discuss the association between nonalcoholic fatty liver disease and insulin resistance Review strategies for the diagnosis of nonalcoholic fatty liver disease
|
Advances in Hepatology: 2005 |
Module 11 of 11 |
|
CME Program Director: Patrick J. Lynch, MD
|
|
Topics covered include:
- Introduction
- Hepatitis B
- Hepatitis C
- Apoptosis
- Assessment of Fibrosis
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the present and future state of select hepatology research Discuss the etiology of cholesterol gallstone disease and the mechanisms involved Describe the role that apoptosis plays in hepatic injury and the various mechanisms involved
|
Animation
Life Cycle of Hepatitis B Virus
Review the steps that make up the replication cycle of hepatitis B virus in hepatocytes, including the targets for anti-HBV therapies.
Life Cycle of Hepatitis B Virus
 |
|
This animation and others are available for use offline from the Download Library.
To download to your own computer and use for personal or teaching purposes, click here
Format: Adobe Flash (.swf) |
File size: 10.90 MB
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|